key: cord-0979471-mjxz5ame authors: Rand, U.; Kupke, S.Y.; Shkarlet, H.; Hein, M.D.; Hirsch, T.; Marichal-Gallardo, P.; Cicin-Sain, L.; Reichl, U.; Bruder, D. title: Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity date: 2021-06-25 journal: bioRxiv DOI: 10.1101/2021.02.19.431972 sha: 2fe050ed5fe2a22d6400102509e954e99b4e674d doc_id: 979471 cord_uid: mjxz5ame SARS-CoV-2 causing COVID-19 emerged in late 2019 and resulted in a devastating pandemic. Although the first approved vaccines were already administered by the end of 2020, worldwide vaccine availability is still limited. Moreover, immune escape variants of the virus are emerging against which the current vaccines may confer only limited protection. Further, existing antivirals and treatment options against COVID-19 only show limited efficacy. Influenza A virus (IAV) defective interfering particles (DIPs) were previously proposed not only for antiviral treatment of the influenza disease but also for pan-specific treatment of interferon (IFN)-sensitive respiratory virus infections. To investigate the applicability of IAV DIPs as an antiviral for the treatment of COVID-19, we conducted in vitro co-infection experiments with cell culture-derived DIPs and the IFN-sensitive SARS-CoV-2 in human lung cells. We show that treatment with IAV DIPs leads to complete abrogation of SARS-CoV-2 replication. Moreover, this inhibitory effect was dependent on janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling. Further, our results suggest boosting of IFN-induced antiviral activity by IAV DIPs as a major contributor in suppressing SARS-CoV-2 replication. Thus, we propose IAV DIPs as an effective antiviral agent for treatment of COVID-19, and potentially also for suppressing the replication of new variants of SARS-CoV-2. . Therapies using recombinant IFNs, however, 93 are cost intensive and pose the risk of unwanted side effects including the formation 94 of auto-antibodies against the cytokine (reviewed in (Sleijfer et al., 2005) ). To 95 prevent this, we wondered whether IAV DIPs would be able to suppress SARS-CoV-2 96 replication through their ability to stimulate a physiological IFN response in target 97 cells. To test this, we produced two promising candidate DIPs, a prototypic, well- 115 In order to test the antiviral efficacy of IAV DIPs on replication of SARS-CoV-2, we In order to test the antiviral efficiency of IAV DIPs in comparison with clinically 128 relevant antivirals, dose-effect curves were generated by testing different 129 concentrations of IAV DIPs for the treatment of SARS-CoV-2-infected cells (Fig. 1C ). As a read-out for SARS-CoV-2 replication, we determined the infectious titer from 131 supernatants at 3 dpi using plaque assays with Vero-6 cells. Please note that 180 SARS-CoV-2 replication via Janus-kinase signaling 181 Next, to investigate our hypothesis whether inhibition of SARS-CoV-2 replication by 182 DIPs was due to their ability to stimulate the IFN system, we used ruxolitinib in co- In order to shed light onto correlates of IAV DIP-mediated SARS-CoV-2 suppression, 204 we used real-time RT-qPCR for quantification of gene expression to assess innate 205 immune responses during co-infections in more detail (Fig. 3A) . We observed a 206 significant upregulation of type I and III IFN (i.e., IFNB1 and IFNL1, respectively) 207 expression at early times following IAV DIP and SARS-CoV-2 co-infection compared 208 to SARS-CoV-2 single infection. Specifically, we detected one to two log 10 higher 209 IFNB1 and IFNL1 mRNA levels at 6 hpi. In addition, canonical antiviral gene Supernatants were collected at indicated time points for quantification of SARS-CoV-2 388 titers (plaque assay) and for protein quantification of secreted IFNs using 389 commercially available ELISA kits (see below). In addition, infected cells were lysed 390 using solution "RL" for subsequent total RNA extraction using the "innuPREP RNA Full dataset (of Fig. 1-4) is available in supplemental Table S1 . Immunity. 585 Passive antibody therapy in COVID-19 Influenza virus DI particles: Defective interfering or delightfully 487 interesting? Collective Viral Spread Mediated by Virion Aggregates 489 Promotes the Evolution of Defective Interfering Particles & 492 KYRATSOUS, C. A. 2020. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 493 mutational escape seen with individual antibodies Differential recognition of viral RNA by RIG-I. Virulence Remdesivir 503 for the Treatment of Covid-19 -Final Report A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-520 19 Type III interferons disrupt the 523 lung epithelial barrier upon viral recognition Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 526 Inducibility and Restricts SARS-CoV-2. mBio SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked 588 by a Clinically Proven Protease Inhibitor Defective Viral Particles Produced in Mast Cells Can Effectively Fight Against Lethal Influenza 597 A Virus Safety, Immunogenicity, and Effectiveness of Defective Viral Particles Arising in Mast 600 Cells Against Influenza in Mice An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Monitoring influenza virus content in 610 vaccine production: precise assays for the quantitation of hemagglutination and 611 neuraminidase activity Favipiravir at 618 high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas 619 hydroxychloroquine lacks activity Strand-specific real-time RT-PCR for distinguishing influenza vRNA, cRNA, and mRNA SARS-CoV-2 ORF3b Is a Potent 625 Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation 626 Variant SARS-CoV-2 vaccines in development Single-Cell Analysis Uncovers a Vast Diversity in Intracellular Viral Defective 630 Interfering RNA Content Affecting the Large Cell-to-Cell Heterogeneity in Influenza A Virus 631 Replication A Novel Type of Influenza A 633 Virus-Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome The type I interferon response in COVID-19: implications for treatment Activation and evasion of type I interferon 639 responses by SARS-CoV-2 Safety and immunogenicity 647 of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two 648 formulations: two open Single-Use Capture 652 Purification of Adeno-Associated Viral Gene Transfer Vectors by Membrane-Based Steric 653 Exclusion Chromatography Steric exclusion 655 chromatography for purification of cell culture-derived influenza A virus using regenerated 656 cellulose membranes and polyethylene glycol 658 Competition between social cheater viruses is driven by mechanistically different cheating 659 strategies Safety and efficacy of inhaled nebulised 663 interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-664 blind Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating 668 Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by 669 A structured summary of a study protocol for a randomised controlled 670 trial Repurposed Antiviral Drugs for Covid-19 -Interim WHO 684 Solidarity Trial Results RIG-I detects viral genomic RNA during 687 negative-strand RNA virus infection Defective interfering 689 influenza A virus protects in vivo against disease caused by a heterologous influenza B virus Side effects of 692 interferon-alpha therapy Association 699 Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill 700 Patients With COVID-19: A Meta-analysis Exploiting Genetic Interference for 702 Defective Interfering Particles of Influenza A Virus in Parallel Continuous Cultures at Two 705 Residence Times-Insights From qPCR Measurements and Viral Dynamics Modeling & 713 INVESTIGATORS, C. C.-B. I. 2020. Effect of Dexamethasone on Days Alive and Ventilator-Free 714 in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: 715 The CoDEX Randomized Clinical Trial Defective viral genomes are key drivers of the virus-host 717 interaction Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) 732 against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil Safety and 738 Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Remdesivir in adults with severe 744 COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Cell culture-based production of 747 defective interfering particles for influenza antiviral therapy The Antiviral and Antitumor Effects of Defective Interfering 751 755 K18-hACE2 mice develop respiratory disease resembling severe COVID-19 RIG-I plays a critical role in 759 negatively regulating granulocytic proliferation Dual-functional peptide with defective interfering genes 762 effectively protects mice against avian and seasonal influenza SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells 775 and Is Detected in Specific Cell Subsets across Tissues Defective Interfering Particles of Negative-Strand RNA Viruses